RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug product announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM®, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.

Medtronic plc data announced reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD).

Blake Insomnia Therapeutics Inc. , a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application for Phase II clinical testing to Health Canada.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that it has completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical gel formulation of thymosin beta 4 (Tß4), in Europe, S. Korea, Japan, Canada and Australia.

Titan Pharmaceuticals, Inc. announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and symptoms of Parkinson's disease.